Gritstone Raises $102m To Climb Cancer Vaccine Mountain
This article was originally published in Scrip
Just as rock climbers use gritstones to scale massive peaks, the San Francisco-based startup Gritstone Oncology raised $102m for the development of neoantigen-containing cancer vaccines that may help the immune system mount a targeted attack against tumors.
You may also be interested in...
Advaxis Advances Personalized Cancer Vaccines With Eye On Manufacturing Time, Cost
Advaxis is developing – now with help from partner Amgen – a personalized immunotherapy strategy with each patient's cancer vaccine based on their own tumor's specific neoepitopes.
BIO: Biotech Funding Captured By Oncology
A report released May 19 from the industry organization confirms that oncology is attracting the most funding, while some other surprising therapeutics areas have become of interest to investors.
Finance Watch: Perlmutter’s Eikon Raises $106m, In-Licenses Pipeline Programs
Private Company Edition: Former Merck R&D head Roger Perlmutter and his new team have accessed drug candidates in oncology and neurodegenerative diseases from three companies, along with new funding. Also, Carmot raised $150m in series E equity and BenchSci brought in $70m.